NCT04857957View on ClinicalTrials.gov

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions
Painful Diabetic Neuropathy
Interventions
DRUG

Oral dose CNTX-6016 or oral dose Placebo

CNTX-6016 or Placebo

Trial Locations (1)

66212

AltaSciences, Overland Park

Sponsors
All Listed Sponsors
lead

Centrexion Therapeutics

INDUSTRY

NCT04857957 - Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN | Biotech Hunter | Biotech Hunter